7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Daroszewska A et al. | Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. | 2004 | J. Bone Miner. Res. | pmid:15312251 |
Liu JM et al. | [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75]. | 2004 | Zhonghua Nei Ke Za Zhi | pmid:15312444 |
Jacobson A et al. | Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts. | 2004 | Biochem. Biophys. Res. Commun. | pmid:15313187 |
Ishida M and Amano S | Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation. | 2004 | J. Bone Miner. Metab. | pmid:15316862 |
Jeffcoate W | Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? | 2004 | Diabetologia | pmid:15322748 |
Liu Z et al. | Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. | 2004 | Protein Pept. Lett. | pmid:15327363 |
Politou M et al. | Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). | 2004 | Br. J. Haematol. | pmid:15327520 |
Erdogan B et al. | Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. | 2004 | Neurol. Res. | pmid:15327755 |
Wada N et al. | Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. | 2004 | Bone | pmid:15336598 |
Amato G et al. | High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. | 2004 | Bone | pmid:15336617 |
Ono Y et al. | Suppressive effect of Kanzo-bushi-to, a Kampo medicine, on collagen-induced arthritis. | 2004 | Biol. Pharm. Bull. | pmid:15340228 |
Sato N et al. | MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. | 2004 | J. Exp. Med. | pmid:15353553 |
Wang L et al. | Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34). | 2004 | J. Bone Miner. Res. | pmid:15355561 |
Nyambo R et al. | Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. | 2004 | J. Bone Miner. Res. | pmid:15355567 |
Roux S and Mariette X | The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. | 2004 | Leuk. Lymphoma | pmid:15359989 |
Wittrant Y et al. | RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. | 2004 | Biochim. Biophys. Acta | pmid:15363860 |
Miyazaki T et al. | Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. | 2004 | J. Cell. Biochem. | pmid:15372622 |
Tian QX and Huang GY | [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts]. | 2004 | Zhongguo Yi Xue Ke Xue Yuan Xue Bao | pmid:15379268 |
Nitta K et al. | Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. | 2004 | Am. J. Kidney Dis. | pmid:15384019 |
Mizutani Y et al. | Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. | 2004 | Cancer | pmid:15386310 |
Burton DW et al. | Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. | 2005 | Prostate | pmid:15389781 |
Abu-Amer Y et al. | TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. | 2004 | J. Cell. Biochem. | pmid:15389885 |
Smith MD | Comment on review on T cells in bone biology. | 2004 | Rheumatology (Oxford) | pmid:15448222 |
Liu JM et al. | Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. | 2005 | Calcif. Tissue Int. | pmid:15455183 |
Boabaid F et al. | Leucine-rich amelogenin peptide: a candidate signaling molecule during cementogenesis. | 2004 | J. Periodontol. | pmid:15455742 |
Collantes Estévez E and González DomÃnguez J | [Bone Paget's disease in the young adult]. | 2004 | Rev Clin Esp | pmid:15456600 |
Wise GE et al. | Regulation of secretion of osteoprotegerin in rat dental follicle cells. | 2004 | Eur. J. Oral Sci. | pmid:15458504 |
Kitaura H et al. | Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. | 2004 | J. Immunol. | pmid:15470024 |
Notoya M et al. | Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells. | 2004 | Biochem. Biophys. Res. Commun. | pmid:15474477 |
Yip KH et al. | Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. | 2004 | J. Bone Miner. Res. | pmid:15476591 |
Dai SM et al. | Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. | 2004 | Ann. Rheum. Dis. | pmid:15479886 |
Wang JC et al. | Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). | 2004 | Exp. Hematol. | pmid:15504545 |
Boabaid F et al. | The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts. | 2004 | J. Periodontol. | pmid:15515341 |
Franck H et al. | Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. | 2004 | J. Rheumatol. | pmid:15517638 |
Ueland T | Bone metabolism in relation to alterations in systemic growth hormone. | 2004 | Growth Horm. IGF Res. | pmid:15519248 |
Vidal K et al. | Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. | 2004 | Am. J. Physiol. Gastrointest. Liver Physiol. | pmid:15521102 |
Chen Q et al. | Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. | 2004 | Horm. Metab. Res. | pmid:15523591 |
Grigorie D et al. | Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. | 2003 | Rom J Intern Med | pmid:15526523 |
Saidenberg-Kermanac'h N et al. | TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. | 2004 | Bone | pmid:15542046 |
Ueland T et al. | Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. | 2004 | J. Am. Coll. Cardiol. | pmid:15542278 |
Demer LL and Abedin M | Skeleton key to vascular disease. | 2004 | J. Am. Coll. Cardiol. | pmid:15542279 |
Franchimont N et al. | Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. | 2004 | Clin. Exp. Immunol. | pmid:15544627 |
Ketteler M et al. | "Missing" inhibitors of calcification: general aspects and implications in renal failure. | 2005 | Pediatr. Nephrol. | pmid:15549415 |
Ichinose Y et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading. | 2004 | Calcif. Tissue Int. | pmid:15549649 |
Kanzaki H et al. | Local OPG gene transfer to periodontal tissue inhibits orthodontic tooth movement. | 2004 | J. Dent. Res. | pmid:15557398 |
Zhang X et al. | Synovial fibroblasts infected with Salmonella enterica serovar Typhimurium mediate osteoclast differentiation and activation. | 2004 | Infect. Immun. | pmid:15557643 |
Theoleyre S et al. | The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. | 2004 | Cytokine Growth Factor Rev. | pmid:15561602 |
Mori T et al. | RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. | 2004 | Nucleic Acids Res. | pmid:15562003 |
Oh ES et al. | Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. | 2005 | Metab. Clin. Exp. | pmid:15562379 |
Ling JQ and Li JP | [Insulin-like growth factor-II and basic fibroblast growth factor affect periodontal ligament cells expressing osteoprotegerin in vitro]. | 2004 | Hua Xi Kou Qiang Yi Xue Za Zhi | pmid:15562643 |
Collin-Osdoby P | Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. | 2004 | Circ. Res. | pmid:15564564 |
Neville-Webbe HL et al. | Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. | 2004 | Breast Cancer Res. Treat. | pmid:15567943 |
Rhee EJ et al. | Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. | 2005 | Clin. Sci. | pmid:15569000 |
Fang TY et al. | [Serum osteoprotegrin and serum bone gamma-carboxyglutamine acid-containing protein are correlated with bone mineral density in normal women]. | 2004 | Zhonghua Yi Xue Za Zhi | pmid:15569454 |
Atkins GJ et al. | Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. | 2005 | J. Cell. Physiol. | pmid:15573398 |
Masui T et al. | Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. | 2005 | Biomaterials | pmid:15576143 |
Herrmann M and Herrmann W | The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. | 2004 | Clin. Chem. Lab. Med. | pmid:15576300 |
Jono S | [Risk factors of atherosclerosis in end-stage renal disease patients]. | 2004 | Clin Calcium | pmid:15576949 |
Shimizu M and Tamura T | [Regulation of bone mineralization by parathyroid hormone]. | 2004 | Clin Calcium | pmid:15577058 |
Ogata H et al. | [Prophylaxis and treatment of adynamic bone]. | 2004 | Clin Calcium | pmid:15577107 |
Manganelli P et al. | OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? | 2005 | Clin. Rheumatol. | pmid:15583970 |
Wang L et al. | Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. | 2005 | Am. J. Physiol. Endocrinol. Metab. | pmid:15585587 |
Byrne FR et al. | CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. | 2005 | Gut | pmid:15591508 |
Lee CK et al. | Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. | 2004 | Arthritis Rheum. | pmid:15593184 |
Zhang D et al. | [Expression of OPG and RANKL at protein level in human periodontal ligament cells and the effect of 1alpha,25(OH)(2) vitamin D(3) on the secretion of OPG protein in vitro]. | 2004 | Beijing Da Xue Xue Bao | pmid:15605102 |
Rajzbaum G et al. | French women, fractures and aortic calcifications. | 2005 | J. Intern. Med. | pmid:15606383 |
Chondrogianni N et al. | Cloning of differentially expressed genes in skin fibroblasts from centenarians. | 2004 | Biogerontology | pmid:15609104 |
Martinetti A et al. | Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. | 2004 | Endocr. Relat. Cancer | pmid:15613451 |
Whyte MP and Mumm S | Heritable disorders of the RANKL/OPG/RANK signaling pathway. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615493 |
Hofbauer LC et al. | The OPG/RANKL/RANK system in metabolic bone diseases. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615494 |
Ritchlin CT et al. | RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615495 |
Clohisy DR and Mantyh PW | Bone cancer pain and the role of RANKL/OPG. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615497 |
Sakai A et al. | Osteoclast development in immobilized bone is suppressed by parathyroidectomy in mice. | 2005 | J. Bone Miner. Metab. | pmid:15616888 |
Sasaki N et al. | Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). | 2005 | J. Bone Miner. Metab. | pmid:15616893 |
Belibasakis GN et al. | The cytolethal distending toxin induces receptor activator of NF-kappaB ligand expression in human gingival fibroblasts and periodontal ligament cells. | 2005 | Infect. Immun. | pmid:15618171 |
Liu XH et al. | Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. | 2005 | Endocrinology | pmid:15618359 |
Cao JJ et al. | Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44. | 2005 | J. Bone Miner. Res. | pmid:15619667 |
Liu PY et al. | A randomized placebo-controlled trial of short-term graded transdermal estradiol in healthy gonadotropin-releasing hormone agonist-suppressed pre- and postmenopausal women: effects on serum markers of bone turnover, insulin-like growth factor-I, and osteoclastogenic mediators. | 2005 | J. Clin. Endocrinol. Metab. | pmid:15623811 |
Zehnder AF et al. | Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. | 2005 | Laryngoscope | pmid:15630389 |
Kees M et al. | Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera. | 2005 | Thromb. Haemost. | pmid:15630493 |
Grzegorzewska AE and MÅ‚ot M | Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631341 |
Grzegorzewska AE and MÅ‚ot M | Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631342 |
Mochizuki S et al. | [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis]. | 2005 | Clin Calcium | pmid:15632471 |
Naumnik W et al. | Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15638385 |
Oh KW et al. | Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. | 2005 | Clin. Endocrinol. (Oxf) | pmid:15638876 |
Marotte H et al. | Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. | 2005 | Arthritis Res. Ther. | pmid:15642135 |
Katsuyama H et al. | Menaquinone-7 regulates the expressions of osteocalcin, OPG, RANKL and RANK in osteoblastic MC3T3E1 cells. | 2005 | Int. J. Mol. Med. | pmid:15647836 |
Altun A et al. | Decreased serum osteoprotegerin levels in patients with cardiac syndrome X. | 2004 | J. Endocrinol. Invest. | pmid:15648548 |
Matayoshi T et al. | Neuropeptide substance P stimulates the formation of osteoclasts via synovial fibroblastic cells. | 2005 | Biochem. Biophys. Res. Commun. | pmid:15649411 |
Lukić IK et al. | Alteration of newly induced endochondral bone formation in adult mice without tumour necrosis factor receptor 1. | 2005 | Clin. Exp. Immunol. | pmid:15654822 |
Subramaniam M et al. | TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. | 2005 | Mol. Cell. Biol. | pmid:15657444 |
Sato K | [Osteoclast-activating factors (OAF)]. | 2004 | Nippon Rinsho | pmid:15658306 |
Kiviranta R et al. | Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. | 2005 | Bone | pmid:15664014 |
Avbersek-Luznik I et al. | Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? | 2005 | Nephrol. Dial. Transplant. | pmid:15665031 |
Bhatia P et al. | Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. | 2005 | Clin. Cancer Res. | pmid:15671541 |
Kiefer JA et al. | The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. | 2004 | Clin. Exp. Metastasis | pmid:15672862 |
Rassi CM et al. | Modulation of osteoclastogenesis in porcine bone marrow cultures by quercetin and rutin. | 2005 | Cell Tissue Res. | pmid:15688188 |
Haynes DR | Bone lysis and inflammation. | 2004 | Inflamm. Res. | pmid:15693607 |
Olesen P et al. | Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. | 2005 | Diabetologia | pmid:15700136 |
Silvestrini G et al. | Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. | 2005 | J. Mol. Histol. | pmid:15704000 |